GO Main Menu Go Main Contents Go Bottom Menu

CelltrionHealthcare

gnb show

MENU

Gnb close

Press Release

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients 2023-12-11

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients   Ventegra® will list VEGZELMA®(bevacizumab-adcd) on its national formulary that serves more than 400 clients and more than 13 million members and patients in the U.S. Celltrion USA completes a contract ...

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs 2023-10-26

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs YUFLYMA® (adalimumab-aaty) was first approved by the Food and Drug Administration on May ...

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease 2023-10-23

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease ZYMFENTRA™ is the first and only FDA-approved subcutaneous (SC) formulation of i...

게시물 검색
  • 5
    Time for a switch for patients with rheumatoid art..
    Expanding clinical experience with biosimilar infliximab CT-P13 10 June 2015, Incheon, South Korea. The comparable safety and efficacy of switching patients to a biosimilar anti-TNF-α monoclonal antibody from the reference medicinal product (RMP) …
    2015-06-10
  • 4
    Patients feel the benefit of biosimilar infliximab..
    Experts share real-world experience with biosimilar infliximab in patients with inflammatory bowel disease 19 May 2015, Incheon, South Korea. Clinical experience of biosimilar infliximab in 78 inflammatory bowel disease (IBD) patients presented…
    2015-05-19
  • 3
    Celltrion launches world’s first biosimilar monocl..
    Now available in 31 countries for the treatment of autoimmune diseases 25 February 2015, Incheon, Republic of Korea. Celltrion Healthcare has today announced the launch of Remsima™ (infliximab) in 12 European markets: Austria, Belgium, Denmark, …
    2015-02-25
  • 2
    Six posters on clinical experience with biosimilar..
    20 February 2015, Barcelona, Spain,Celltrion Healthcarehastoday announced data demonstrating thatthe world’s first biosimilar monoclonal antibody (mAb) infliximabis an effective treatment option for patients with the chronic debilitatingautoimmunedis…
    2015-02-20
  • 1
    Data show the world’s first EMA-approved biosimila..
    Cost savings could help improve patient access to life-changing treatment 20 February 2015, Barcelona, Spain. Celltrion Healthcare has today announced data demonstrating the healthcare savings achievable by using Remsima™ (CT-P13), a biosimilar mo…
    2015-02-20